IP Library Granted Patent US 9,115,095
Granted Patent B2
US 9,115,095 · App. 14/298,516 · Granted Aug 25, 2015

Phosphinate ruthenium complexes

Inventors: Christophe Claude Parsy (Jacou, FR); Francois-Rene Alexandre (Montpellier, FR); Florence Marie-Emilie Bonnaterre (Romainville, FR); Dominique Surleraux (Wauthier-Braine, BE)
Assignee: Idenix Pharmaceuticals, Inc.
C07D255/04B01J31/2278C07C67/30C07C67/333C07D207/22C07D207/46C07D487/04C07F9/3229C07F9/4419C07F9/4476C07F15/0046
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,115,095
App. No.
14/298,516
Granted
Aug 25, 2015
Kind
B2
Abstract

Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Claims (87)

1. A method of catalyzing an olefin metathesis reaction, comprising contacting a ruthenium complex of Formula I with an olefin compound;

wherein:

L is a neutral ligand;

R 1 is C 1-12 alkyl, C 3-10 cycloalkyl, C 6-14 aryl, heteroaryl, heterocyclyl, or —NR 3b R 3c ;

R 2 is H, C 1-12 alkyl, C 3-10 cycloalkyl, or C 6-14 aryl;

R 3 is halo, cyano, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, heteroaryl, heterocyclyl, —C(O)R 3a , —C(O)OR 3a , —C(O)NR 3b R 3c , —OR 3a , —NR 3b R 3c , —NR 3a C(O)R 3b , —NR 3a C(O)OR 3b , —NR 3a S(O) 2 R 3b , —PR 3a R 3b , —P(OR 3a )R 3b , —P(OR 3a )(OR 3b ), —P(O)R 3a R 3b , —P(O)(OR 3a )R 3b , —P(O)(OR 3a )(OR 3b ), —S(O) 2 R 3a , or —SO 2 NR 3b R 3c ,

R 4 is C 1-12 alkyl, C 3-10 cycloalkyl, C 7-15 aralkyl, or —C(R 4a R 4b )C(O)NR 4c R 4d ;

R 5 is hydrogen, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C 3-10 cycloalkyl, or C 6-14 aryl;

each R 3a and R 3d is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, heteroaryl, or heterocyclyl;

each R 3b and R 3c is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, heteroaryl, or heterocyclyl; or R 3b and R 3c together with the N atom form a heteroaryl or heterocyclyl;

R 4a and R 4b are each independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, C 6-14 aryl, or C 7-15 aralkyl; and

R 4c and R 4d are each independently hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, C 6-14 aryl, or C 7-15 aralkyl; or R 4c and R 4d together with the N atom form heterocyclyl;

X 1 and X 2 are each independently an anionic ligand;

Y is a bond or —NR b —;

Z is O or S; and

n is an integer of 0, 1, 2, or 3;

wherein each alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclyl, and heteroaryl is optionally substituted with one or more groups, each independently selected from (a) cyano, halo, or nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q; or (c) —C(O)R a , —C(O)OR a , —C(O)NR b R c , —C(NR a )NR b R c , —OR a , —OC(O)R a , —OC(O)OR a , —OC(O)NR b R c , —OC(═NR a )NR b R c , —OS(O)R a , —OS(O) 2 R a , —OS(O)NR b R c , —OS(O) 2 NR b R c , —NR b R c , —NR a C(O)R d , —NR a C(O)OR d , —NR a C(O)NR b R c , —NR a C(═NR d )NR b R c , —NR a S(O)R d , —NR a S(O) 2 R d , —NR a S(O)NR b R c , —NR a S(O) 2 NR b R c , —PR a R d , —P(OR a )R d , —P(OR a )(OR d ), —P(O)R a R d , —P(O)(OR a )R d , —P(O)(OR a )(OR d ), —SR a , —S(O)R a , —S(O) 2 R a , or —SO 2 NR b R c ; wherein each R a , R b , R c , and R d is independently hydrogen; C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl, each optionally substituted with one or more substituents Q; or R b and R c together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more substituents Q;

wherein each Q is independently selected from the group consisting of (i) cyano, halo, or nitro; (ii) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) —C(O)R e , —C(O)OR e , —C(O)NR f R g , —C(NR e )NR f R g , —OR e , —OC(O)R e , —OC(O)OR e , —OC(O)NR f R g , —OC(═NR e )NR f R g , —OS(O)R e , —OS(O) 2 R e , —OS(O)NR f R g , —OS(O) 2 NR f R g , —NR f R g , —NR e C(O)R h , —NR e C(O)OR h , —NR e C(O)NR f R g , —NR e C(═NR h )NR f R g , —NR e S(O)R h , —NR e S(O) 2 R h , —NR e S(O)NR f R g , —NR e S(O) 2 NR f R g , —PR e R h , —P(OR e )R h , —P(OR e )(OR h ), —P(O)R e R h , —P(O)(OR e )R h , —P(O)(OR e )(OR h ), —SR e , —S(O)R e , —S(O) 2 R e , or —S(O) 2 NR f R g ; wherein each R e , R f , R g , and R h is independently hydrogen; C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or R f and R g together with the N atom to which they are attached form heterocyclyl.

2. The method of claim 1 , wherein the ruthenium complex has Formula Ia, Formula Ib, or Formula Ic:

3. The method of claim 1 , wherein L is a heterocyclic carbene or phosphine, wherein the heterocyclic carbene is optionally substituted with one or more substituents.

4. The method of claim 3 , wherein the heterocyclic carbene is selected from:

wherein:

each R 11 and R 12 is independently C 1-6 alkyl or C 6-14 aryl; and

each R 13 , R 14 , R 15 , and R 16 is independently hydrogen, cyano, nitro, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 6-14 aryl, heteroaryl, or heterocyclyl;

wherein each alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, and heteroaryl is optionally substituted with one or more substituents.

5. The method of claim 4 , wherein the heterocyclic carbene is selected from:

6. The method of claim 3 , wherein the phosphine is PR 17 R 18 R 19 , wherein R 17 , R 18 , and R 19 are each independently C 1-12 alkyl or C 6-14 aryl, each optionally substituted with one or more substituents.

7. The method of claim 1 , wherein

X 1 is halide, —C(O)R X , or —OC(O)R X , R x is alkyl, optionally substituted with one or more halides;

X 2 is halide, —C(O)R X , or —OC(O)R X , wherein R X is alkyl, optionally substituted with one or more halides;

R 1 is C 1-5 alkyl, C 5-6 cycloalkyl, C 6-14 aryl, heteroaryl, heterocyclyl, or —NR 3b R 3c ;

R 2 is C 1-5 alkyl or C 5-6 cycloalkyl;

R 3 is halo, cyano, nitro, —C(O)OR 3a , —NR 3a S(O) 2 R 3b , —P(O)(OR 3a )R 3b , or —SO 2 NR 3b R 3c ;

R 4 is C 1-5 alkyl or C 5-6 cycloalkyl;

R 5 is hydrogen, C 1-5 alkyl, or C 5-6 cycloalkyl;

Z is O; or

n is 0.

8. The method of claim 1 , wherein the complex is selected from:

wherein:

Cmpd No.

Y

R 1

R 11

R 12

AP

A bond

Mes

Mes

AQ

A bond

Mes

Mes

AR

A bond

Mes

Mes

AT

A bond

Mes

Mes

C5

A bond

—N(CH 3 ) 2

Mes

Mes

D4

A bond

Mes

Mes

E6

—NH—

Mes

Mes

G2

A bond

2-MePh

2-MePh

wherein Mes is 2,4,6-trimethylphenyl and 2-MePh is 2-methylphenyl.

9. The method of claim 1 , wherein the olefin compound has one terminal olefin group.

10. The method of claim 1 , wherein the olefin compound has two terminal olefin groups.

11. The method of claim 1 , wherein the molar ratio between the ruthenium complex and the olefin compound is no greater than 0.5.

12. The method of claim 1 , wherein the molar ratio between the ruthenium complex and the olefin compound is no greater than 0.05.

13. The method of claim 1 , wherein the olefin metathesis reaction is a ring closure metathesis reaction.

14. The method of claim 1 , wherein the olefin metathesis reaction is an acyclic diene metathesis polymerization reaction.

15. The method of claim 1 , wherein the olefin metathesis reaction is a ring opening metathesis polymerization reaction.

16. The method of claim 1 , wherein the olefin metathesis reaction is a ring opening metathesis reaction.

17. The method of claim 1 , wherein the olefin metathesis reaction is a cross metathesis reaction.

Assignments (2)
CHANGE OF NAME Recorded Jul 30, 2015
From: IDENIX PHARMACEUTICALS, INC.
To: IDENIX PHARMACEUTICALS LLC
Reel/Frame 036233/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: PARSY, CHRISTOPHE CLAUDE; ALEXANDRE, FRANCOIS-RENE; BONNATERRE, FLORENCE; SURLERAUX, DOMINIQUE
To: IDENIX PHARMACEUTICALS, INC.
Reel/Frame 035580/0767 →
Continuity (7)
Continuation 13910885 · Jun 5, 2013
Continuation 13765578 · Feb 12, 2013
Division 13627828 · Sep 26, 2012
Division 13146877
Provisional Application 61231408 · Aug 5, 2009
Provisional Application 61149662 · Feb 3, 2009
Related Publication 20140350241A1 · Nov 27, 2014